02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
13:09 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Addiction Mouse studies suggest inhibitors of the heroin metabolite 6-monoacetylmorphine could help treat prenatal heroin addiction. In pregnant mouse dams exposed to heroin, an anti-6-monoacetylmorphine antibody decreased blood levels of morphine -- a heroin...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
18:04 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Thrombocytopenia Mouse studies suggest depleting NK cells or inhibiting NK cell activation could help treat fetal/neonatal alloimmune thrombocytopenia (FNAIT). In a mouse model of FNAIT, a tool antibody that depletes NK cells decreased uterine...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Endothelial cell nitric oxide synthase 3 (NOS3; eNOS)

Genitourinary disease INDICATION: Genitourinary Patient sample and mouse studies suggest promoting NOS3 activity with Viagra sildenafil could help prevent preeclampsia. In patient placental tissue samples or vascular endothelium from a mouse model of preeclampsia, markers...
07:00 , Mar 31, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: E. coli DNA adenine methyltransferase (Dam)

Infectious disease INDICATION: Bacterial infection Cell studies suggest inhibiting E. coli Dam could help enhance the sensitivity of the bacterial infection to antibiotics. In a cultured strain of E. coli, knockout of Dam plus an...
07:00 , Jul 17, 2014 |  BC Innovations  |  Targets & Mechanisms

New route for old cancer agents

Researchers at the University of Wisconsin-Madison and Cellectar Biosciences Inc. have exploited differences in lipid architecture between cancer and normal cells to create compounds that deliver radiolabels selectively to different types of malignant cells while...
08:00 , Jan 9, 2014 |  BC Innovations  |  Cover Story

Light it up

Poor tumor definition is a central challenge in cancer surgery, which aims to remove all malignant cells while preserving normal tissue. Now, a team from The University of Texas Southwestern Medical Center has designed fluorescent...
08:00 , Jan 5, 2012 |  BC Innovations  |  Tools & Techniques

Eau de fluorescence

Researchers from the National Cancer Institute and The University of Tokyo have developed a topical fluorescent probe that they have shown can detect residual tumor cells in mice during cancer surgery. 1 The researchers will...
08:00 , Nov 2, 2009 |  BioCentury  |  Strategy

An acquirer's golden rule

Peer Schatz, CEO of Qiagen N.V. , says he's not a fan of building companies through acquisition. But since he took over the helm in 2004, the sample and assay technologies company has been one...